Embodiments of the present invention are directed to compositions and methodsfor the treatment of purpura.Preferred compositions comprise an a adrenergic receptor agonist selected fromselective .alpha.1 adrenergic receptor agonist, selective .alpha.2adrenergic receptor agonist, non-selective .alpha.1/.alpha.2 adrenergicreceptor agonist, agents with .alpha.2 adrenergic receptor agonist activityandcombinations thereof, in a pharmaceutically acceptable carrier in order totreat and improve the cosmetic appearance of hemorrhagic(purpuric) lesions in the skin.
